Health & Fitness
Health and Fitness
Health and Fitness
Wed, February 6, 2013Tue, February 5, 2013Mon, February 4, 2013Sun, February 3, 2013Sat, February 2, 2013Fri, February 1, 2013Thu, January 31, 2013Wed, January 30, 2013Tue, January 29, 2013Mon, January 28, 2013Sun, January 27, 2013Sat, January 26, 2013Fri, January 25, 2013Thu, January 24, 2013Wed, January 23, 2013Tue, January 22, 2013Mon, January 21, 2013Fri, January 18, 2013Thu, January 17, 2013Wed, January 16, 2013Tue, January 15, 2013Mon, January 14, 2013Regeneron to Report Fourth Quarter and Full Year 2012 Financial and Operating Results and Host Conference Call and Webcast on F
Published in Health and Fitness on Monday, January 28th 2013 at 13:16 GMT by Market Wire
Regeneron to Report Fourth Quarter and Full Year 2012 Financial and Operating... -- TARRYTOWN, N.Y., Jan. 28, 2013 /PRNewswire/ --
TARRYTOWN, N.Y., Jan. 28, 2013 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)today announced that it will report its fourth quarter and full year 2012 financial and operating results on Thursday, February 14, 2013, before the U.S. financial markets open. The Company will host a conference call and simultaneous webcast at 8:30 AM EST that day.
Conference Call Information
To access this call, dial (888) 660-6127 (U.S.) or (973) 890-8355 (International). A link to the webcast may be accessed from the 'Events and Presentations' page of Regeneron's website at [ www.regeneron.com ]. A replay of the conference call and webcast will be archived on the Company's website and will be available for 30 days.
About Regeneron Pharmaceuticals, Inc.
Regeneron is a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron markets medicines for eye diseases, colorectal cancer, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including hypercholesterolemia, rheumatoid arthritis, and asthma. For additional information about the company, please visit [ www.regeneron.com ].
Contact Information: | |
Michael Aberman, M.D. | Peter Dworkin |
Investor Relations | Corporate Communications |
914-847-7799 | 914.847.7640 |
SOURCE Regeneron Pharmaceuticals, Inc.
RELATED LINKS
[ http://www.regeneron.com ]
